Mesalamine ER 0.375 refers to a specific dosage form of mesalamine, an anti-inflammatory drug used to treat ulcerative colitis. The "ER" designation indicates extended-release, meaning the medication is designed to release mesalamine slowly over time. The 0.375 likely refers to a capsule size or a specific formulation where this dosage is relevant [1].
What is mesalamine used for?
Mesalamine, also known as 5-ASA, is a common treatment for inflammatory bowel disease (IBD), particularly ulcerative colitis. It works by reducing inflammation in the colon. Mesalamine ER formulations aim to deliver the drug directly to the inflamed areas of the gastrointestinal tract, potentially improving efficacy and reducing side effects [1][2].
How does mesalamine ER work?
Extended-release mesalamine formulations are designed to bypass absorption in the upper gastrointestinal tract and deliver the active ingredient to the colon. This targeted delivery is achieved through various technologies, such as pH-dependent coatings or matrix systems, which release mesalamine as the formulation travels through the intestines [2].
What are different types of mesalamine formulations?
Mesalamine is available in various forms, including delayed-release capsules, extended-release granules, suppositories, and enemas. The specific formulation chosen often depends on the location and extent of inflammation in the colon [1][2].
What is the difference between mesalamine and its brand names?
Mesalamine is the generic name for the active ingredient. Brand names are specific products manufactured by pharmaceutical companies that contain mesalamine. Examples of brand names include Apriso, Asacol, Delzicol, Lialda, and Pentasa, each with its own specific extended-release technology and dosage [1].
When does patent protection for mesalamine drugs expire?
Patent protection for mesalamine drugs varies by specific formulation and manufacturer. DrugPatentWatch.com tracks patent expiry dates for various pharmaceutical products. Information on the patent status of specific mesalamine formulations can be found by searching their database [3].
Can generic versions of mesalamine ER be released?
Generic versions of mesalamine ER drugs can be released after the relevant patents expire and regulatory approval is obtained. The availability of generics depends on the patent landscape and the success of any patent challenges [3].
What are the risks and side effects of mesalamine?
Common side effects of mesalamine can include headache, nausea, diarrhea, abdominal pain, and rash. More serious, though rare, side effects can involve kidney problems, severe allergic reactions, and blood disorders [1][4]. Patients should discuss any concerns with their healthcare provider.
How is mesalamine ER dosed?
Dosage for mesalamine ER depends on the specific product, the condition being treated, and individual patient response. The 0.375 dosage likely refers to a specific capsule size or formulation. It is crucial to follow the prescribing doctor's instructions regarding dosage and administration [1].
Sources:
1. https://www.nps.org.au/australian-medicines-handbook/medicines/mesalazine
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888155/
3. https://drugpatentwatch.com/
4. https://www.nhs.uk/medicines/mesalazine/